.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Army
Merck
Chubb
US Department of Justice
QuintilesIMS
UBS
Dow
Teva
Cerilliant

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 010379

« Back to Dashboard
NDA 010379 describes CYTOMEL, which is a drug marketed by King Pharms and is included in one NDA. It is available from two suppliers. Additional details are available on the CYTOMEL profile page.

The generic ingredient in CYTOMEL is liothyronine sodium. There are four drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.

Summary for 010379

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Thyroid)
Formulation / Manufacturing:see details

Pharmacology for NDA: 010379

Ingredient-typeTriiodothyronine

Suppliers and Packaging for NDA: 010379

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CYTOMEL
liothyronine sodium
TABLET;ORAL 010379 NDA Physicians Total Care, Inc. 54868-1750 54868-1750-0 100 TABLET in 1 BOTTLE, PLASTIC (54868-1750-0)
CYTOMEL
liothyronine sodium
TABLET;ORAL 010379 NDA Physicians Total Care, Inc. 54868-1750 54868-1750-1 30 TABLET in 1 BOTTLE, PLASTIC (54868-1750-1)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 0.005MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 0.025MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 0.05MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Colorcon
Accenture
Mallinckrodt
QuintilesIMS
Harvard Business School
Argus Health
Cerilliant
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot